Tirzepatide vs semaglutide in obesity; GLP1a use is complicated; HF outcomes; the misuse of meta-analyses in HF; and a breakthrough in HF care are the topics John Mandrola, MD, covers this week.

This podcast is intended for healthcare professionals only.

To read a partial transcript or to comment, visit:

https://www.medscape.com/twic

I. SURMOUNT 5

• Clinicaltrials.gov https://clinicaltrials.gov/study/NCT05822830
• Press Release

II. Access to GLP-1 Agonist Drugs

• CMS statement https://www.cms.gov/newsroom/press-releases/biden-harris-administration-announces-medicare-advantage-and-medicare-part-d-prescription-drug

III. SUMMIT TRIAL commentary

Has Tirzepatide Scaled the HFpEF/Obesity SUMMIT?

https://www.medscape.com/viewarticle/has-tirzepatide-scaled-hfpef-obesity-summit-2024a1000m2h

IV. Blank Spot in HF Evidence – All cause hospitalizations

• Sayed and colleagues What Is Success in HF Trials? https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2827168
• EMPEROR-Preserved https://www.nejm.org/doi/full/10.1056/NEJMoa2107038
• Mayo Observational Study 10.1016/j.mayocp.2016.11.009
• DIG Trial https://jamanetwork.com/journals/jama/fullarticle/195990

V. Misuse of Meta-analysis by HF Community

• Lu and colleagues PARAGON/PARADIGM Meta-analysis https://jamanetwork.com/journals/jamacardiology/fullarticle/2823259
• Desai 2004 https://jamanetwork.com/journals/jama/fullarticle/199995
• PARADIGM HF https://www.nejm.org/doi/full/10.1056/NEJMoa1409077
• PARAGON HF https://www.nejm.org/doi/full/10.1056/NEJMoa1908655

VI Integration of Palliative Care Into HF Care

• Chuzi and colleagues Palliative Care in HF 10.1016/j.cardfail.2024.10.435
• Kotecha and colleagues Beta-blocker Metaanalysis 10.1016/S0140-6736(14)61373-8

You may also like:

The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington

Questions or feedback, please contact [email protected]